Senseonics Holdings, Inc. (SENS)
| Market Cap | 502.83M +70.3% |
| Revenue (ttm) | 48.55M +90.6% |
| Net Income | -109.39M |
| EPS | -2.26 |
| Shares Out | 52.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 988,511 |
| Open | 9.45 |
| Previous Close | 9.75 |
| Day's Range | 9.07 - 9.66 |
| 52-Week Range | 4.79 - 10.64 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 13.67 (+43.74%) |
| Earnings Date | Nov 9, 2026 |
About SENS
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company ser... [Read more]
Financial Performance
In 2025, Senseonics Holdings's revenue was $35.26 million, an increase of 56.89% compared to the previous year's $22.47 million. Losses were -$69.11 million, -12.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for SENS stock is "Buy." The 12-month stock price target is $13.67, which is an increase of 43.74% from the latest price.
News
Senseonics initiates first-in-human clinical study evaluating Freedom
Senseonics (SENS) announced the initiation of its first-in-human clinical study evaluating Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device ...
Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World's First CGM System with No On-body Component
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics' innovation roadmap, with potential launch in 2028
Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continu...
Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuo...
Senseonics initiated with an Equal Weight at Barclays
Barclays initiated coverage of Senseonics (SENS) with an Equal Weight rating and $10 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive…
Beta Bionics to integrate iLet Bionic Pancreas, mint with Eversense 365
Beta Bionics (BBNX) announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery systems with Senseonics’ (SENS) Eversense 365 continuous glucose monitoring system...
Senseonics partners with Beta Bionics to integrate Eversense 365
Senseonics (SENS) announced a partnership with Beta Bionics (BBNX). The companies are collaborating to integrate Eversense 365 CGM with Beta Bionics’ iLet Bionic Pancreas automated insulin delivery sy...
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancre...
Senseonics To Participate in Upcoming Institutional Investor Conferences
GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continu...
Senseonics reports Q2 EPS (63c), consensus (62c)
Reports Q2 revenue $14.5M, consensus $12.91M. U.S. revenue grew more than 150% year-over-year to $12.6M. “This was the strongest quarter in Senseonics (SENS)’ history, achieving record revenue and exp...
Senseonics Holdings Earnings Call Transcript: Q2 2026
Q2 2026 saw record revenue growth of 120% year-over-year, with U.S. revenue up 150% and gross margin reaching 59%. Full-year guidance was raised for both revenue and margin, supported by strong commercial execution, a successful European transition, and a strengthened balance sheet.
Senseonics Holdings Earnings release: Q2 2026
Senseonics Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Senseonics Holdings Quarterly report: Q2 2026
Senseonics Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people w...
Senseonics price target lowered to $18 from $20 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on Senseonics (SENS) to $18 from $20 and keeps an Outperform rating on the shares. The firm adjusted targets in the…
Senseonics announces further data from study of Eversense 365
Senseonics (SENS) announces further data from a large real-world evidence study which reveals sustained accuracy, performance and positive impact of Eversense 365 in both open-loop and closed-loop sys...
Senseonics Holdings Transcript: Investor update
Commercial integration and DTC marketing have driven strong patient and prescriber growth, with Eversense 365 showing robust real-world performance and high retention. The pipeline includes Gemini and Freedom, aiming for fully implantable, invisible CGMs by 2028. Financials are strong, with >80% revenue growth and improved margins.
Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026
GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, ...
Senseonics Holdings Transcript: AGM 2026
The meeting, held virtually, covered six proposals including director elections, executive compensation, auditor ratification, share authorization increase, and an equity plan. All proposals passed, with results to be reported on Form 8-K.
Senseonics price target lowered to $14 from $18.50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Senseonics (SENS) to $14 from $18.50 and keeps a Buy rating on the shares. The firm cites equity dilution for the target…
Senseonics price target lowered to $8 from $9 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Senseonics (SENS) to $8 from $9 and keeps a Hold rating on the shares following what the firm calls “a…
Senseonics price target lowered to $12 from $20 at Lake Street
Lake Street analyst Ben Haynor lowered the firm’s price target on Senseonics (SENS) to $12 from $20 and keeps a Buy rating on the shares after the company reported a…
Senseonics reports Q1 EPS (71c), consensus (70c)
Reports Q1 revenue $9.34M, consensus $9.83M. Tim Goodnow, President and Chief Executive Officer of Senseonics (SENS), said, “This was our first quarter as a fully-integrated commercial organization in...
Senseonics Holdings Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 85% year-over-year to $11.7M with gross margin at 58%, driven by strong Eversense 365 adoption and successful U.S. commercial integration. Full-year revenue guidance was raised, and over $100M in new capital was secured to support growth and product pipeline.
Senseonics Holdings Earnings release: Q1 2026
Senseonics Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.